Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Magnetic Resonance Imaging | Research

Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer"

Authors: Christine Deutschmann, Christian F. Singer, Daphne Gschwantler-Kaulich, Georg Pfeiler, Carmen Leser, Pascal A. T. Baltzer, Thomas H. Helbich, Christine Kraus, Ricarda Korbatits, Alaa Marzogi, Paola Clauser

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Residual fibroglandular breast tissue (RFGT) following a mastectomy has been claimed to be associated with the occurrence of an in-breast local recurrence (IBLR) or new primary tumor (NP). Yet, scientific evidence proving this assumption is lacking. The primary aim of the study was to verify whether RFGT following a mastectomy is a risk factor for an IBLR or NP.

Methods

This retrospective analysis included all patients that underwent a mastectomy and were followed up at the Department of Obstetrics and Gynecology of the Medical University of Vienna between 01.01.2015 and 26.02.2020. RFGT volume (assessed on magnetic resonance imaging) was correlated with the prevalence of an IBLR and a NP.

Results

A total of 105 patients (126 breasts) following a therapeutic mastectomy were included. After a mean follow-up of 46.0 months an IBLR had occurred in 17 breasts and a NP in 1 breast. A significant difference in RFGT volume was observed between the disease-free cohort and the subgroup with an IBLR or NP (p = .017). A RFGT volume of ≥ 1153 mm3 increased the risk by the factor 3.57 [95%CI 1.27; 10.03].

Conclusions

RFGT volume is associated with an increased risk for an IBLR or NP.
Appendix
Available only for authorised users
Literature
1.
go back to reference Al-Himdani S, et al. Prediction of margin involvement and local recurrence after skin-sparing and simple mastectomy. Eur J Surg Oncol. 2016;42(7):935–41.CrossRefPubMed Al-Himdani S, et al. Prediction of margin involvement and local recurrence after skin-sparing and simple mastectomy. Eur J Surg Oncol. 2016;42(7):935–41.CrossRefPubMed
2.
go back to reference De La Cruz L, et al. Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review. Ann Surg Oncol. 2015;22(10):3241–9.CrossRefPubMed De La Cruz L, et al. Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review. Ann Surg Oncol. 2015;22(10):3241–9.CrossRefPubMed
3.
go back to reference Kaas R, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg. 2010;251(3):488–92.CrossRefPubMed Kaas R, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg. 2010;251(3):488–92.CrossRefPubMed
4.
go back to reference Mutter RW, et al. Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes. Breast Cancer Res Treat. 2015;153(1):183–90.CrossRefPubMed Mutter RW, et al. Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes. Breast Cancer Res Treat. 2015;153(1):183–90.CrossRefPubMed
5.
go back to reference Rebbeck TR, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22(6):1055–62.CrossRefPubMed Rebbeck TR, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22(6):1055–62.CrossRefPubMed
6.
go back to reference Domchek SM, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75.CrossRefPubMedPubMedCentral Domchek SM, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75.CrossRefPubMedPubMedCentral
7.
go back to reference Heemskerk-Gerritsen BA, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol. 2013;24(8):2029–35.CrossRefPubMed Heemskerk-Gerritsen BA, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol. 2013;24(8):2029–35.CrossRefPubMed
8.
go back to reference Skytte AB, et al. Breast cancer after bilateral risk-reducing mastectomy. Clin Genet. 2011;79(5):431–7.CrossRefPubMed Skytte AB, et al. Breast cancer after bilateral risk-reducing mastectomy. Clin Genet. 2011;79(5):431–7.CrossRefPubMed
9.
go back to reference Zhou X, Li Y. Local recurrence after breast-conserving surgery and mastectomy following neoadjuvant chemotherapy for locally advanced breast cancer - a meta-analysis. Breast Care (Basel). 2016;11(5):345–51.CrossRefPubMed Zhou X, Li Y. Local recurrence after breast-conserving surgery and mastectomy following neoadjuvant chemotherapy for locally advanced breast cancer - a meta-analysis. Breast Care (Basel). 2016;11(5):345–51.CrossRefPubMed
10.
go back to reference Heemskerk-Gerritsen BA, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14(12):3335–44.CrossRefPubMedPubMedCentral Heemskerk-Gerritsen BA, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14(12):3335–44.CrossRefPubMedPubMedCentral
11.
go back to reference Woitek R, et al. MRI-based quantification of residual fibroglandular tissue of the breast after conservative mastectomies. Eur J Radiol. 2018;104:1–7.CrossRefPubMedPubMedCentral Woitek R, et al. MRI-based quantification of residual fibroglandular tissue of the breast after conservative mastectomies. Eur J Radiol. 2018;104:1–7.CrossRefPubMedPubMedCentral
12.
go back to reference Torresan RZ, et al. Evaluation of residual glandular tissue after skin-sparing mastectomies. Ann Surg Oncol. 2005;12(12):1037–44.CrossRefPubMed Torresan RZ, et al. Evaluation of residual glandular tissue after skin-sparing mastectomies. Ann Surg Oncol. 2005;12(12):1037–44.CrossRefPubMed
13.
go back to reference Dreadin J, et al. Risk of residual breast tissue after skin-sparing mastectomy. Breast J. 2012;18(3):248–52.CrossRefPubMed Dreadin J, et al. Risk of residual breast tissue after skin-sparing mastectomy. Breast J. 2012;18(3):248–52.CrossRefPubMed
14.
go back to reference Zippel D, et al. Magnetic resonance imaging (MRI) evaluation of residual breast tissue following mastectomy and reconstruction with silicone implants. Clin Imaging. 2015;39(3):408–11.CrossRefPubMed Zippel D, et al. Magnetic resonance imaging (MRI) evaluation of residual breast tissue following mastectomy and reconstruction with silicone implants. Clin Imaging. 2015;39(3):408–11.CrossRefPubMed
15.
go back to reference Giannotti DG, et al. Analysis of skin flap thickness and residual breast tissue after mastectomy. Int J Radiat Oncol Biol Phys. 2018;102(1):82–91.CrossRefPubMed Giannotti DG, et al. Analysis of skin flap thickness and residual breast tissue after mastectomy. Int J Radiat Oncol Biol Phys. 2018;102(1):82–91.CrossRefPubMed
16.
go back to reference Tewari M, et al. Residual breast tissue in the skin flaps after Patey mastectomy. Indian J Med Res. 2004;119(5):195–7.PubMed Tewari M, et al. Residual breast tissue in the skin flaps after Patey mastectomy. Indian J Med Res. 2004;119(5):195–7.PubMed
17.
go back to reference Grinstein O, et al. Residual Glandular Tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies. Surg Oncol. 2019;29:126–33.CrossRefPubMed Grinstein O, et al. Residual Glandular Tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies. Surg Oncol. 2019;29:126–33.CrossRefPubMed
18.
go back to reference Frey JD, et al. Mastectomy flap thickness and complications in nipple-sparing mastectomy: objective evaluation using magnetic resonance imaging. Plast Reconstr Surg Glob Open. 2017;5(8): e1439.CrossRefPubMedPubMedCentral Frey JD, et al. Mastectomy flap thickness and complications in nipple-sparing mastectomy: objective evaluation using magnetic resonance imaging. Plast Reconstr Surg Glob Open. 2017;5(8): e1439.CrossRefPubMedPubMedCentral
19.
go back to reference De Vita R, et al. Outcome evaluation after 2023 nipple-sparing mastectomies: our experience. Plast Reconstr Surg. 2017;139(2):335e–47e.CrossRefPubMed De Vita R, et al. Outcome evaluation after 2023 nipple-sparing mastectomies: our experience. Plast Reconstr Surg. 2017;139(2):335e–47e.CrossRefPubMed
20.
go back to reference Sardanelli F, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46(8):1296–316.CrossRefPubMed Sardanelli F, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46(8):1296–316.CrossRefPubMed
21.
go back to reference Yushkevich PA, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006;31(3):1116–28.CrossRefPubMed Yushkevich PA, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006;31(3):1116–28.CrossRefPubMed
22.
go back to reference Li Q, et al. Risk factors for locoregional recurrence after postmastectomy radiotherapy in breast cancer patients with four or more positive axillary lymph nodes. Curr Oncol. 2014;21(5):e685–90.CrossRefPubMedPubMedCentral Li Q, et al. Risk factors for locoregional recurrence after postmastectomy radiotherapy in breast cancer patients with four or more positive axillary lymph nodes. Curr Oncol. 2014;21(5):e685–90.CrossRefPubMedPubMedCentral
23.
go back to reference Karlsson P, et al. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an international breast cancer study group report. Ann Oncol. 2012;23(11):2852–8.CrossRefPubMedPubMedCentral Karlsson P, et al. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an international breast cancer study group report. Ann Oncol. 2012;23(11):2852–8.CrossRefPubMedPubMedCentral
24.
go back to reference Petit JY, et al. Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. Ann Oncol. 2012;23(8):2053–8.CrossRefPubMed Petit JY, et al. Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. Ann Oncol. 2012;23(8):2053–8.CrossRefPubMed
25.
go back to reference Mamtani A, et al. Impact of age on locoregional and distant recurrence after mastectomy for ductal carcinoma in situ with or without microinvasion. Ann Surg Oncol. 2019;26(13):4264–71.CrossRefPubMedPubMedCentral Mamtani A, et al. Impact of age on locoregional and distant recurrence after mastectomy for ductal carcinoma in situ with or without microinvasion. Ann Surg Oncol. 2019;26(13):4264–71.CrossRefPubMedPubMedCentral
26.
go back to reference Glorioso JM, et al. Margin proximity correlates with local recurrence after mastectomy for patients not receiving adjuvant radiotherapy. Ann Surg Oncol. 2017;24(11):3148–56.CrossRefPubMed Glorioso JM, et al. Margin proximity correlates with local recurrence after mastectomy for patients not receiving adjuvant radiotherapy. Ann Surg Oncol. 2017;24(11):3148–56.CrossRefPubMed
27.
go back to reference Fitzsullivan E, et al. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013;20(13):4103–12.CrossRefPubMedPubMedCentral Fitzsullivan E, et al. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013;20(13):4103–12.CrossRefPubMedPubMedCentral
28.
go back to reference Kaidar-Person O, et al. Residual glandular breast tissue after mastectomy: a systematic review. Ann Surg Oncol. 2020;27(7):2288–96.CrossRefPubMed Kaidar-Person O, et al. Residual glandular breast tissue after mastectomy: a systematic review. Ann Surg Oncol. 2020;27(7):2288–96.CrossRefPubMed
29.
go back to reference Ebctcg, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.CrossRef Ebctcg, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.CrossRef
30.
go back to reference Papassotiropoulos B, et al. Prospective evaluation of residual breast tissue after skin- or nipple-sparing mastectomy: results of the SKINI-Trial. Ann Surg Oncol. 2019;26(5):1254–62.CrossRefPubMed Papassotiropoulos B, et al. Prospective evaluation of residual breast tissue after skin- or nipple-sparing mastectomy: results of the SKINI-Trial. Ann Surg Oncol. 2019;26(5):1254–62.CrossRefPubMed
Metadata
Title
Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer"
Authors
Christine Deutschmann
Christian F. Singer
Daphne Gschwantler-Kaulich
Georg Pfeiler
Carmen Leser
Pascal A. T. Baltzer
Thomas H. Helbich
Christine Kraus
Ricarda Korbatits
Alaa Marzogi
Paola Clauser
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10764-y

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine